Skip to main content

Call for papers - Advances in pre-clinical cancer models

Guest Editors:
Ryan C. Fields: Washington University School of Medicine in St. Louis, USA
Anna Golebiewska: Luxembourg Institute of Health, Luxembourg

Submission Status: Open   |   Submission Deadline: 30 April 2023


BMC Cancer is calling for submissions to our Collection on novel in vitro and in vivo cancer models which can help elucidating the mechanisms involved in tumour onset and progression, leading to the development of new therapeutic treatments.

Meet the Guest Editors

Back to top

Ryan C. Fields: Washington University School of Medicine in St. Louis, USA

Prof. Fields is the Chief of Surgical Oncology and serves as Director of the Washington University Solid Tumor Tissue Bank and Registry.  He is also the Co-Leader of the Solid Tumor Therapeutics Program (STTP) and the Melanoma and Cutaneous Oncology Program at the Alvin J. Siteman NCI-designated Comprehensive Cancer Center at Washington University School of Medicine in St. Louis, Missouri.  His research focuses on three main areas: (1) mechanisms of cancer metastases, (2) cancer “-omics”, and (3) novel in vitro and small animal models of cancer. In the area of cancer modelling, he is working to improve the evaluation of diagnostics and therapeutics by developing novel small animal and in vitro models of cancer. He has significant expertise and experience leading large-scale human tumor collection efforts.  He has an IRB-approved tumor collection and patient-derived xenografting (PDX), cell line, and organoid creation effort.  He works in a multi-disciplinary, collaborative effort to evaluate and translate these model systems into tools that can be used to evaluate novel therapeutics in translational oncology. 

Anna Golebiewska: Luxembourg Institute of Health, Luxembourg 

Dr. Anna Golebiewska is Group leader of the NORLUX Neuro-Oncology laboratory at the Department of Cancer Research, Luxembourg Institute of Health. She has a background in molecular and cellular biology and obtained her PhD in stem cell research. Her work focuses on understanding brain tumor biology and development of clinically relevant animal models. She is particularly interested in the various aspects of tumor heterogeneity and plasticity. Her lab developed a large collection of glioma patient-derived organoids and orthotopic xenografts for preclinical research and drug testing.


About the collection

BMC Cancer is calling for submissions to our Collection on pre-clinical cancer models.

Cancer models are indispensable research tools, as they help elucidating the mechanisms involved in tumour onset and progression, leading to the development of new therapeutic treatments. While widely-used conventional two-dimensional cell models have been the gold standard for many decades, some of their main limitations include the lack of representation of the stromal population, the absence of a three-dimensional structure, and a poor representation of inter-tumour and intra-tumour heterogeneity. Therefore, a multitude of novel cancer models are emerging, which can advance the understanding of tumour pathophysiology and behavior. This will ultimately help improving patients’ clinical outcomes, through the introduction of more personalized and targeted treatments in the clinical setting.

In recognition of the growing field of research, BMC Cancer welcomes submissions to a newly launched collection ‘Advances in pre-clinical cancer models’. Topics of interest for this special issue include but are not limited to:

  • Scaffold-based in vitro models
  • 3D cell cultures
  • Co-culture settings
  • Tumour organoids
  • Large and small animal models 
  • Genetically engineered cell lines and animal models
  • Chemically induced tumour models
  • Xenotransplantation models (Patient derived xenografts, cell-line derived xenograft)
  • Allotransplantation models


Image credit: Hyungkeun/ Getty

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Advances in pre-clinical cancer models" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.